Parabilis Medicines (NASDAQ: PBLS) has unveiled plans for a $600 million initial public offering, marketing 33.33 million shares at a price range of $17.00 to $19.00 per share. At the midpoint of the proposed range, the Cambridge, Massachusetts-based biotechnology company would command an estimated market capitalization of approximately $2.14 billion. The offering is being led by Leerink Partners, BofA Securities, Evercore ISI, Guggenheim Securities, and LifeSci Capital.
Parabilis is developing a new class of medicines known as Helicons, engineered peptides designed to target disease-driving proteins that have historically been considered inaccessible to conventional therapies. By combining artificial intelligence-driven computational modeling with proprietary peptide engineering capabilities, the company aims to unlock a large universe of biologically validated targets that have remained beyond the reach of traditional small molecules and antibody-based drugs. Management believes this platform has the potential to address some of the most challenging targets across oncology and other serious diseases.
The company's lead candidate, zolucatetide, is the first known therapy designed to directly inhibit the interaction between β-catenin and TCF transcription factors, a key driver of the Wnt/β-catenin signaling pathway implicated in numerous cancers. The pathway has long been considered one of the most attractive yet difficult targets in oncology drug development. To date, zolucatetide has been evaluated in more than 150 patients and has generated encouraging clinical data across multiple tumor types driven by β-catenin and APC mutations.
The most advanced opportunity for zolucatetide is in desmoid tumors, a rare and often debilitating soft tissue tumor driven by aberrant Wnt signaling. As of February 2026, Parabilis reported tumor reductions in every response-evaluable patient and a 74% objective response rate among patients with at least two post-baseline scans. The company plans to launch a global registrational Phase 3 study in the first half of 2027, positioning desmoid tumors as the potential first commercial indication for the program.
Beyond desmoid tumors, Parabilis is evaluating zolucatetide in familial adenomatous polyposis (FAP), hepatocellular carcinoma, colorectal cancer, and several additional rare tumor types characterized by activation of the Wnt/β-catenin pathway. Management believes the breadth of activity observed to date supports the possibility of developing zolucatetide across multiple indications, creating what it describes as a potential "pipeline-in-a-product" opportunity.
The broader Helicon platform extends well beyond zolucatetide. The company is advancing preclinical programs targeting ERG-driven prostate cancer and androgen receptor degradation, both of which focus on historically difficult intracellular targets. Parabilis also recently entered into a strategic collaboration with Regeneron Pharmaceuticals to explore Antibody-Helicon Conjugates, an emerging therapeutic approach that combines antibody targeting with intracellular protein modulation. Concurrent with the IPO, Regeneron has agreed to purchase approximately $75 million of Parabilis common stock in a private placement, providing additional validation of the company's technology and development strategy.
Like many emerging biotechnology companies, Parabilis remains focused on advancing its pipeline rather than generating revenue. The company reported a net loss of $145.9 million in 2025, compared with a net loss of $117.9 million in 2024, reflecting continued investment in research and clinical development. As of March 31, 2026, Parabilis held approximately $329 million in cash and cash equivalents, a figure that would increase substantially following completion of both the IPO and the Regeneron investment.
Founded in 2015 and backed by more than $800 million in private capital from investors including ARCH Venture Partners, Fidelity, GV, RA Capital, venBio, and others, Parabilis enters the public markets as one of the larger biotechnology offerings of 2026. With a differentiated platform, encouraging early clinical results, and a lead program approaching registrational development, investors will be watching closely to determine whether the company can translate its scientific promise into a new generation of medicines targeting some of oncology's most difficult disease pathways.